B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NR4A1

MOLECULAR TARGET

nuclear receptor subfamily 4 group A member 1

UniProt: P22736NCBI Gene: 31645 compounds

NR4A1 (nuclear receptor subfamily 4 group A member 1) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NR4A1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alitretinoin4.0355
2meclofenamic acid3.5032
3pristimerin3.1422
4vidofludimus2.4811
5celastrol2.309

About NR4A1 as a Drug Target

NR4A1 (nuclear receptor subfamily 4 group A member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented NR4A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NR4A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.